Pharmena SA
WSE:PHR
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| PL |
P
|
Pharmena SA
WSE:PHR
|
38.5m PLN |
Loading...
|
|
| FR |
|
L'Oreal SA
PAR:OR
|
188.7B EUR |
Loading...
|
|
| UK |
|
Unilever PLC
LSE:ULVR
|
105.2B GBP |
Loading...
|
|
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.1T INR |
Loading...
|
|
| UK |
|
HALEON PLC
LSE:HLN
|
33.6B GBP |
Loading...
|
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
31.5B USD |
Loading...
|
|
| DE |
|
Beiersdorf AG
XETRA:BEI
|
17.2B EUR |
Loading...
|
|
| JP |
|
Kao Corp
TSE:4452
|
2.8T JPY |
Loading...
|
|
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.1T INR |
Loading...
|
|
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD |
Loading...
|
|
| IN |
|
Dabur India Ltd
NSE:DABUR
|
803.2B INR |
Loading...
|
Market Distribution
| Min | -535 500% |
| 30th Percentile | 18.1% |
| Median | 30.2% |
| 70th Percentile | 55.9% |
| Max | 807.1% |
Other Profitability Ratios
Pharmena SA
Glance View
PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. The company is headquartered in Lodz, Woj. Lodzkie and currently employs 24 full-time employees. The company went IPO on 2008-08-25. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Pharmena SA is 84.5%, which is above its 3-year median of 56%.
Over the last 3 years, Pharmena SA’s Gross Margin has increased from 53.1% to 84.5%. During this period, it reached a low of 2.9% on Mar 31, 2024 and a high of 84.5% on Sep 30, 2025.
